Navigation Links
Vasogen Announces Implementation of Strategic Restructuring Plan
Date:4/14/2008

MISSISSAUGA, ON, April 14 /PRNewswire-FirstCall/ - Vasogen Inc. (NASDAQ:VSGN; TSX:VAS), today announced that it has implemented a strategic restructuring plan to significantly reduce its cash burn rate and focus its efforts on opportunities that the Board and management believe are most likely to provide long-term shareholder value. This plan re-focuses Vasogen's resources on the development of its VP series of drugs while the Company seeks alternatives to fund further development of the Celacade(TM) System, the Company's technology for the treatment of chronic heart failure. As a result of this restructuring, which reduces Vasogen's work force by approximately 85%, the Company expects to have approximately two years of cash resources.

As previously reported, Vasogen has encountered significant delays with the FDA regarding the design of ACCAIM II, a clinical trial to support an application for U.S. market approval of Celacade for the treatment of patients with NYHA Class II heart failure. Given these delays, Vasogen's current lack of access to capital, and the uncertainty surrounding the FDA's continued opposition to a relatively small trial utilizing a Bayesian statistical design, the Company has placed on hold plans to fund ACCLAIM II. The Company will, however, continue to work with the FDA towards finalizing the design of ACCLAIM II, and will evaluate potential strategic alternatives to fund such a study. In addition, subsequent to the recent receipt of a much lower than anticipated revenue forecast for Celacade from its European marketing partner, Grupo Ferrer, Vasogen plans to discontinue operational and financial support for European commercialization and is exploring alternative strategies with Ferrer. Ferrer's sales forec
'/>"/>

SOURCE Vasogen Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Vasogen Announces Third Quarter Conference Call and Webcast of Bio InvestorForum 2007 Presentation
2. Vasogen Announces Third Quarter 2007 Results
3. Vasogen to Webcast Presentations at Three Upcoming Healthcare Conferences
4. Vasogen Provides an Update on ACCLAIM-II Preparations
5. Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure
6. Vasogen to Conduct Year-end 2007 Conference Call
7. Vasogen Announces 2007 Year-End Results
8. The Lancet Publishes Vasogens ACCLAIM Results
9. Vasogens Research Published in European Journal of Neuroscience
10. Vasogen to Present at the BIO CEO & Investor Conference and Participate on the Non-Cancer Immunotherapy Panel
11. Vasogen Provides Update on ACCLAIM II Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... July 10, 2014 Women in ... access to an additional family planning option. Sayana® ... contraception at all levels of the health system ... of a widely used contraceptive—Pfizer’s Depo-Provera® (depot medroxyprogesterone ... Faso is the first of four African countries ...
(Date:7/10/2014)... July 10, 2014 Unraveling life’s mysteries ... The Archer Family purchased a DNA test ... but ended up with a lifetime of memories, sharing, ... the family members’ DNA genuinely brought the family closer ... search deeper into genetic history and prior to taking ...
(Date:7/10/2014)... Ind. , July 10, 2014 /PRNewswire/ ... its use of capnography for respiratory monitoring ... group of healthcare leaders in embracing state-of-the-art ... how effectively patients are breathing and can ... occurs. By measuring the amount of carbon ...
(Date:7/10/2014)... 10, 2014   Ceres, Inc . (Nasdaq: ... announced today financial results for the three months ended ... business. Ceres reported that the company and ... this growing season in Brazil, which concluded in June, ... sorghum evaluation areas for part of the growing season. ...
Breaking Biology Technology:Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9
... 17 , - MedITEX IVF Facilitates ... - MedITEX from 28 June to 1 ... The IT consulting company CRITEX, which specialises in ... fertilisation, MedITEX IVF,at the 25th Annual Meeting of the European Society ...
... , FREMONT, Calif., June 16 Microfluidic Systems, ... patent number 7,541,166, entitled "Sonication to Selectively Lyse ... the process of differential extraction of male/female DNA ... in a wide variety of biological sample processes ...
... and Webcast on Wednesday, June 17 at 8:30 a.m. Eastern ... Savient Pharmaceuticals, Inc. (Nasdaq: SVNT ) announced ... Food and Drug Administration (FDA) recommended by a vote of ... PEGylated uricase enzyme, be granted marketing approval by the FDA ...
Cached Biology Technology:New IVF Software MedITEX to be Presented at the ESHRE Exhibition 2MicroFluidic Systems (MFSI) Receives Patent for Method to Selectively Process Different Biological Cell Types for Analysis. 2FDA Appointed Arthritis Advisory Committee Recommends U.S. Food and Drug Administration Approval for KRYSTEXXA(TM) for Refractory Chronic Gout 2FDA Appointed Arthritis Advisory Committee Recommends U.S. Food and Drug Administration Approval for KRYSTEXXA(TM) for Refractory Chronic Gout 3FDA Appointed Arthritis Advisory Committee Recommends U.S. Food and Drug Administration Approval for KRYSTEXXA(TM) for Refractory Chronic Gout 4
(Date:7/10/2014)... 2014  Pomerantz LLP has filed a class ... the "Company")(NYSE-MKT: PVCT) and certain of its officers.  ... Court, Middle District of Tennessee ... class consisting of all persons or entities who ... 17, 2013 and May 22, 2014, both dates ...
(Date:7/10/2014)... , July 2, 2014 NXT-ID, Inc., (OTCQB: NXTD) a biometric ... CEO Mr. Gino Pereira was interviewed on July ... Tampa Florida . Mr. Pereira discusses the ... Cedric Harris and how the Wocket™ aims to replace ... Cedric Harris tells Gino he has ...
(Date:7/10/2014)... Fingerprint Cards, (FPC,s) new mobile touch ... Asian OEM has selected FPC1021 for a flagship model with ...   FPC is proud to announce this DW ... for start of mass production in August 2014. FPC has ... delivery in the first half of July. The OEM wants ...
Breaking Biology News(10 mins):SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 3Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 2Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 3Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 4FPC Wins DW and Initial Ramp Order for FPC1021 Touch Sensor for Flagship Smartphone from Asian OEM 2
... made the world,s temperature records available via Google Earth. ... temperature dataset is one of the most widely used records ... allows users to scroll around the world, zoom in on ... data more easily than ever before. Users can drill ...
... . . . With the installation this ... Arena will become the first major sports venue to ... 85 percent more efficient than conventional arena metal halide ... LED North America incorporate an Oak Ridge National Laboratory-developed ...
... of 11,500 km2 within the Arabian Peninsula. Both Qatar,s ... decades, thus putting a strong pressure on native species. ... has triggered a variety of studies of its dwindling ... the occurrence of 21 lizard species, two of them ...
Cached Biology News:World temperature records available via Google Earth 2Story tips from the Department of Energy's Oak Ridge National Laboratory, February 2014 2Story tips from the Department of Energy's Oak Ridge National Laboratory, February 2014 3Where do lizards in Qatar live? First distribution maps for the state 2
Smac/DIABLO (CT) - IgG for Western Blotting, Host: Rabbit Family: Smac/DIABLO...
Mouse Amphiregulin MAb (Clone 206220)...
Anti-Digoxigenin-AP, Fab fragments; from sheep...
The antibody recognizes the peptide sequence ESESQGPK (aa 441-448) of human class III beta-tubulin specific for neurones....
Biology Products: